The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture

Nephron - Experimental Nephrology

Volumn 120, Issue 2, 2012, Pages

  Hainz, Nadine ^a   Thomas, Susanne ^a   Neubert, Kirsten ^b,c   Meister, Silke ^b,c   Benz, Kerstin ^a   Rauh, Manfred ^a   Daniel, Christoph ^a   Wiesener, Michael ^a,c   Voll, Reinhard E ^b,c   Amann, Kerstin ^a  

^a Nephropathology Krankenhausstrasse 8 10 ^*  (Germany)

^b Department of Internal Medicine   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoimmune disease; Podocyte; Proteasome inhibition; Proteinuria; Systemic lupus erythematosus

Indexed keywords

BORTEZOMIB; COLLAGEN TYPE 4; PROTEASOME INHIBITOR; BORONIC ACID DERIVATIVE; PROTEASOME; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL LOSS; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; GLOMERULUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY STRUCTURE; KIDNEY TUBULE DAMAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ELECTRON MICROSCOPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE; METABOLISM; MORTALITY; MOUSE STRAIN; PATHOPHYSIOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; BORONIC ACIDS; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; KIDNEY GLOMERULUS; KIDNEY TUBULES; LUPUS NEPHRITIS; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICROSCOPY, ELECTRON; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856153814     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000334955     Document Type: Article

References (49)

1. Lipsky PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
2. Mills JA: Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871-1879.
3. Manz RA, Radbruch A: Plasma cells for a lifetime? Eur J Immunol 2002; 32: 923-927. (Pubitemid 34428806)
4. Miller JJ 3rd, Cole LJ: Resistance of longlived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6 mercaptopurine and actinomycin D. USNRDL-TR-67-24. Res Dev Tech Rep 1967; 11: 1-20.
5. Slifka MK, Ahmed R: Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10: 252-258. (Pubitemid 28286950)
6. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390. (Pubitemid 15093080)
7. Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G, Berek C, Hiepe F, Krenn V, Radbruch A, Manz RA: Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001; 31: 2726-2732. (Pubitemid 32898740)
8. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA: Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577-1584. (Pubitemid 38780412)
9. van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zijde CM, Oudeman- Gruber NJ, de Vries E, Radl J, Vossen JM: The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 1996; 87: 818-826. (Pubitemid 26030340)
10. Ang HA, Apperley JF, Ward KN: Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. Blood 1997; 89: 4646-4651. (Pubitemid 27260277)
11. Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360. (Pubitemid 38579481)
12. Hideshima T, Richardson PG, Anderson KC: Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol2003; 7: 191-204.
13. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jack HM, Voll RE: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792. (Pubitemid 46383406)
14. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. JClin Oncol 2005; 23: 630-639. (Pubitemid 46224241)
15. Maseda D, Meister S, Neubert K, Herrmann M, Voll RE: Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008; 15: 600-612 (Pubitemid 351267310)
16. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916. (Pubitemid 43882644)
17. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755. (Pubitemid 351951516)
18. Wellmann U, Letz M, Schneider A, Amann K, Winkler TH: An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB ! NZW)F1 mice. Int Immunol 2001; 13: 1461-1469. (Pubitemid 33133875)
19. Haas CS, Amann K, Schittny J, Blaser B, Muller U, Hartner A: Glomerular and renal vascular structural changes in alpha8 integrin- deficient mice. J Am Soc Nephrol 2003; 14: 2288-2296. (Pubitemid 37052375)
20. el Nahas AM, Bassett AH, Cope GH, Le Carpentier JE: Role of growth hormone in the development of experimental renal scarring.Kidney Int 1991; 40: 29-34.
21. Goumenos DS, Brown CB, Shortland J, el Nahas AM: Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant 1994; 9: 1418-1425. (Pubitemid 24310284)
22. Dimmler A, Haas CS, Cho S, Hattler M, Forster C, Peters H, Schocklmann HO, Amann K: Laser capture microdissection and realtime PCR for analysis of glomerular endothelin- 1 gene expression in mesangiolysis of rat anti-Thy 1.1 and murine Habu snake venom glomerulonephritis. Diagn Mol Pathol 2003; 12: 108-117. (Pubitemid 36627193)
23. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE: Prognostic factors in lupus nephritis - contribution of renal histologic data. Am J Med 1983; 75: 382-391. (Pubitemid 13005770)
24. Bush KT, Goldberg AL, Nigam SK: Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulumchaperones, and thermotolerance. J Biol Chem 1997; 272: 9086-9092. (Pubitemid 27154911)
25. Sarkozi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M, Eder S, Rudnicki M, Rosenkranz AR, Mayer B, Mayer G, Schramek H: Bortezomib-induced survivalsignals and genes in human proximal tubularcells. J Pharmacol Exp Ther 2008; 327: 645-656.
26. Gass JN, Gifford NM, Brewer JW: Activation of an unfolded protein response during differentiation of antibody-secreting B cells. JBiol Chem 2002; 277: 49047-49054. (Pubitemid 35470877)
27. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH: Plasma cell differentiation and the unfoldedprotein response intersect at the transcription factor XBP-1. Nat Immunol 2003; 4: 321-329. (Pubitemid 36432313)
28. Liu CY, Kaufman RJ: The unfolded protein response. J Cell Sci 2003; 116: 1861-1862. (Pubitemid 36622284)
29. Liu Y, Wu J, Wu H, Wang T, Gan H, Zhang X, Liu Y, Li R, Zhao Z, Chen Q, Guo M,Zhang Z: UCH-L1 expression of podocytesin diseased glomeruli and in vitro. J Pathol 2009; 217: 642-653.
30. Lecanda J, Ganapathy V, D'Aquino-ArdalanC, Evans B, Cadacio C, Ayala A, Gold LI: TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest. Cell Cycle 2009; 8: 742-756.
31. Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G, Grassi G: Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009; 91: 373-382.
32. Huber JM, Tagwerker A, Heininger D, MayerG, Rosenkranz AR, Eller K: The proteasome inhibitor bortezomib aggravates renal ischemia- reperfusion injury. Am J Physiol Renal Physiol 2009; 297:F451-F460.
33. Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, ShanklandSJ: The cyclin kinase inhibitor p21WAF1/ CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999; 56: 1691-1699. (Pubitemid 29518169)
34. Wolf G, Schanze A, Stahl RA, Shankland SJ,Amann K: p27(Kip1) knockout mice are protectedfrom diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int 2005; 68: 1583-1589. (Pubitemid 43169903)
35. Ko BS, Chang TC, Chen CH, Liu CC, KuoCC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY: Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappaB. Life Sci 2010; 86: 199-206.
36. Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S: Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets 2010; 10: 55-67.
37. Zheng L, Sinniah R, Hsu SI: Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006; 37: 637-647. (Pubitemid 43956530)
38. Ashizawa M, Miyazaki M, Abe K, Furusu A, Isomoto H, Harada T, Ozono Y, Sakai H, Koji T, Kohno S: Detection of nuclear factor-kappaB in IgA nephropathy using southwestern histochemistry. Am J Kidney Dis 2003; 42: 76-86. (Pubitemid 36813986)
39. Mudge SJ, Paizis K, Auwardt RB, Thomas RJ, Power DA: Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis. Kidney Int 2001; 59: 923-931. (Pubitemid 32206855)
40. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G: Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179-2193. (Pubitemid 35434863)
41. Cybulsky AV, Takano T, Papillon J, Bijian K, Guillemette J, Kennedy CR: Glomerular epithelial cell injury associated with mutant alpha- actinin-4. Am J Physiol Renal Physiol 2009; 297:F987-F995.
42. Blattner SM, Kretzler M: Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton. Curr Opin Nephrol Hypertens 2005; 14: 404-410. (Pubitemid 40863081)
43. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez- Perez JC, Allen PG, Beggs AH, Pollak MR: Mutations in ACTN4, encoding alpha-actinin- 4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256. (Pubitemid 30132192)
44. D'Amico G: Tubulointerstitium as predictor of progression of glomerular diseases. Nephron 1999; 83: 289-295.
45. Liu L, Yang C, Herzog C, Seth R, Kaushal GP: Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosisinducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol2010; 79: 137-146.
46. Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A: Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 2009; 20: 123-130.
47. Itoh M, Takaoka M, Shibata A, Ohkita M, Matsumura Y: Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 2001; 298: 501-507. (Pubitemid 32673400)
48. Takaoka M, Itoh M, Kohyama S, Shibata A, Ohkita M, Matsumura Y: Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. J Cardiovasc Pharmacol 2000; 36:S225-S227
49. Takaoka M, Ohkita M, Itoh M, Kobayashi Y, Okamoto H, Matsumura Y: A proteasome inhibitor prevents vascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2001; 28: 466-468. (Pubitemid 32538917)